Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E21.36 EPS (ttm)4.10 Insider Own0.10% Shs Outstand1.63B Perf Week0.13%
Market Cap142.40B Forward P/E13.49 EPS next Y6.49 Insider Trans-26.33% Shs Float1.59B Perf Month22.32%
Income6.62B PEG1.55 EPS next Q1.38 Inst Own70.90% Short Float1.25% Perf Quarter20.43%
Sales26.71B P/S5.33 EPS this Y16.20% Inst Trans0.97% Short Ratio3.35 Perf Half Y33.31%
Book/sh3.77 P/B23.20 EPS next Y17.56% ROA10.00% Target Price79.41 Perf Year34.42%
Cash/sh4.43 P/C19.76 EPS next 5Y13.76% ROE119.70% 52W Range55.06 - 89.69 Perf YTD39.70%
Dividend2.56 P/FCF52.07 EPS past 5Y10.90% ROI18.00% 52W High-2.46% Beta1.50
Dividend %2.93% Quick Ratio1.30 Sales past 5Y8.00% Gross Margin76.70% 52W Low58.87% ATR1.61
Employees30000 Current Ratio1.40 Sales Q/Q7.60% Oper. Margin36.70% RSI (14)73.92 Volatility1.69% 2.19%
OptionableYes Debt/Eq6.20 EPS Q/Q21.30% Profit Margin24.80% Rel Volume1.14 Prev Close87.41
ShortableYes LT Debt/Eq5.63 EarningsOct 27 BMO Payout58.90% Avg Volume5.96M Price87.48
Recom2.40 SMA207.85% SMA5016.03% SMA20029.40% Volume6,806,950 Change0.08%
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Sep-24-17 07:00AM  AbbVie's Unfazed by the Risk of Generic Humira Motley Fool
Sep-22-17 03:14PM  Gilead's (GILD) Epclusa Receives Label Expansion in Canada Zacks
07:43AM  3 Big Biotech Stocks to Buy This Fall Motley Fool
07:00AM  AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors PR Newswire
06:41AM  Ask a Fool! We Answer Your Healthcare Questions on Trials, Patents, and Pharmacy Retailers Motley Fool
Sep-21-17 01:32PM  Bulls bet their chips on this casino name CNBC Videos
12:45PM  How AbbVie Inc (ABBV) Delivered A Better ROE Than Its Industry Simply Wall St.
Sep-20-17 09:11AM  Sell Johnson & Johnson because of its 'stretched' valuation: Goldman CNBC
08:02AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Sep-19-17 03:14PM  Roche (RHHBY) Announces Positive Data on Leukemia Drug Zacks
06:45AM  3 Value Stocks at 52-Week Highs Still Worth Buying Motley Fool
03:30AM  3 High-Yield Pharmaceutical Stocks Motley Fool
Sep-18-17 11:29AM  AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA/VENCLYXTO (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia PR Newswire
10:15AM  J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU Zacks
Sep-16-17 08:03AM  Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020? Motley Fool
Sep-15-17 02:21PM  AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Investor's Business Daily
Sep-14-17 11:00AM  Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx Zacks
10:31AM  How Safe Is Abbott Labs' Dividend? Motley Fool
08:01AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Sep-13-17 07:01PM  Cramer's lightning round: Here's where Qualcomm went wron... CNBC Videos
06:51PM  Cramer's lightning round: Here's where Qualcomm went wrong CNBC
02:38PM  AbbVie Is Likely to Correct: Book Some Profits
08:33AM  Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data Zacks
08:01AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: AbbVie and Intercept Pharmaceuticals ACCESSWIRE
06:38AM  5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing Motley Fool
Sep-12-17 10:59AM  AbbVie's RA Candidate Meets Primary Endpoint in Phase III Zacks
08:17AM  These 3 Stocks Have Lifted Vanguard High Dividend Yield ETF in 2017 Motley Fool
08:02AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
06:48AM  5 Things Regeneron's CEO Said as the Biotech Stock Sank Motley Fool
Sep-11-17 04:30PM  Why Achillion Pharmaceuticals Crashed 22.2% Today Motley Fool
03:30PM  Regeneron: When Good Isn't Good Enough
11:16AM  AbbVie says deaths in arthritis trial not linked to drug Reuters
08:54AM  5 solid stocks for a rocky September MarketWatch
08:42AM  AbbVie reports two patient deaths in rheumatoid arthritis study Reuters
08:01AM  AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis PR Newswire
Sep-09-17 12:00PM  3 Stocks That Put Walt Disney's Returns to Shame Motley Fool
06:03AM  AbbVie Announces 3rd-Quarter Dividend
Sep-08-17 06:02PM  AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb Zacks
05:42PM  Regeneron's Cemiplimab Gains Breakthrough Therapy Status Zacks
04:50PM  The Hot Stock: AbbVie Jumps 6.1%
02:58PM  AbbVie: Up, Up and Away!
11:03AM  AbbVie Declares Quarterly Dividend PR Newswire
08:37AM  AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher Zacks
07:18AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc Motley Fool
03:00AM  Stocks Flashing Renewed Technical Strength: Bristol-Myers Squibb Investor's Business Daily
Sep-07-17 07:30PM  AbbVie Scores 2 Wins: 1 Threatens Regeneron Motley Fool +6.14%
06:10PM  3 Stocks Soaring Today
04:53PM  AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study InvestorPlace
04:38PM  Why the Biosimilar Drug Revolution Hasn't Arrived Bloomberg
04:36PM  Why Cabela's, Fitbit, and AbbVie Jumped Today Motley Fool
03:08PM  US STOCKS-Wall St slips as media stocks, Hurricane Irma weigh Reuters
10:52AM  Why Regeneron Is Getting Smoked
10:45AM  AbbVie Submits NDA for Endometriosis Candidate to the FDA Zacks
10:26AM  Why Biotech Can Keep Adding To Its Gains
08:57AM  AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year PR Newswire
08:03AM  AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis PR Newswire
07:30AM  AbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference PR Newswire
06:04AM  5 Things Gilead Sciences' Management Just Said That You'll Want to Know Motley Fool
06:00AM  This Shield of Patents Protects the Worlds Best-Selling Drug Bloomberg
Sep-06-17 12:30PM  Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead Zacks
08:01AM  AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain PR Newswire
03:00AM  Grifols Shows Market Leadership With Jump To 82 RS Rating Investor's Business Daily
Aug-31-17 03:52PM  Trump has pledged $1 million to Harvey relief, White House says CNBC
08:43AM  The Smart Money Likes These 5 Stocks Motley Fool
Aug-30-17 08:48AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG Zacks
Aug-29-17 02:15PM  3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock InvestorPlace
09:39AM  The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance Zacks
08:03AM  3 Healthcare Stocks to Buy With Dividends Yielding More Than 3% Motley Fool
05:00AM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors InvestorPlace
Aug-28-17 07:19PM  Roche's Gazyva Gets Priority Review for Follicular Lymphoma Zacks
04:36PM  ETFs with exposure to AbbVie, Inc. : August 28, 2017 Capital Cube
04:34PM  Top Stock Reports for AbbVie, Broadcom & 21st Century Fox Zacks
03:31PM  3 High-Yield Dividend Aristocrat Stocks Motley Fool
Aug-27-17 02:02PM  Why I Love AbbVie Inc. Motley Fool
Aug-26-17 12:03PM  Is the System Rigged Against Biosimilars? Motley Fool
Aug-25-17 11:13AM  Biogen's Humira Biosimilar Imraldi Gets Approval in EU Zacks
09:18AM  Pharma Stocks That Could Move On New Data
Aug-24-17 08:57PM  Samsung, Biogen version of AbbVie's Humira approved in Europe Reuters
05:43PM  This biotech stock is about to take off: Trader CNBC Videos
Aug-23-17 06:41PM  Top 3 Stocks for Retirees to Consider Motley Fool
02:15PM  AbbVie, Inc. : ABBV-US: Dividend Analysis : July 14th, 2017 (record date) : By the numbers : August 23, 2017 Capital Cube
09:07AM  Key Developments for Allergan in 2Q17 Market Realist
09:03AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : August 23, 2017 Capital Cube
08:04AM  3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences Motley Fool
07:37AM  How Allergans International Segment Performed in 2Q17 Market Realist
Aug-22-17 07:06PM  5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed
Aug-21-17 02:19PM  Gilead: Where's the Urgency?
01:31PM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive InvestorPlace
11:46AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017 Capital Cube
08:21AM  Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
Aug-20-17 07:22AM  3 Dividend Stocks I'd Buy Right Now Motley Fool
Aug-18-17 10:32AM  AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada Zacks
Aug-17-17 10:05AM  Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst
09:03AM  AbbVie's MAVIRET Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes CNW Group
07:35AM  3 Value Stocks for Retirees Motley Fool
Aug-16-17 09:32AM  What Does AbbVies Dividend Curve Look Like? Market Realist
08:00AM  3 Dividend Healthcare Stocks Motley Fool
Aug-14-17 05:31PM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : August 14, 2017 Capital Cube
03:42PM  Big-name U.S. hedge funds shed healthcare stocks during the rally in Q2 Reuters
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM